Psilocybin's Lasting Benefits Prove Elusive in Mice, Bay Area Study Finds

Five Bay Area laboratories collaborated to investigate whether psilocybin, the active compound in magic mushrooms, produces lasting reductions in anxiety and depression-like behaviors in mice. The multi-lab study, which pooled resources and data, found limited evidence of long-term therapeutic effects, challenging some assumptions about the drug's potential for treating mood disorders. Researchers conducted a series of behavioral tests on mice after psilocybin administration, but the results did not consistently show sustained improvements. This outcome raises questions about the translatability of psychedelic research from animal models to human clinical trials, where psilocybin has shown promise for conditions like treatment-resistant depression. The study underscores the complexity of psychedelic pharmacology and the need for rigorous, reproducible science. As interest in psychedelic therapy grows, these findings highlight the importance of understanding exactly how and when these compounds work—and for whom.